A comparison of treatment with adefovir and entecavir for chronic hepatitis B in China: The 2-year results of a prospective study

Hepatitis Monthly

Volumn 11, Issue 1, 2011, Pages 27-32

  Chen, En Qiang ^a,b   Zhou, Tao You ^a,b   Liu, Li ^a,b   Liu, Cong ^a,b   Lei, Ming ^a,b   Tang, Hong ^a,b  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Adefovir; Chronic hepatitis B; Comparison; Entecavir

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ENTECAVIR; HEPATITIS B(E) ANTIGEN;

ADULT; ARTICLE; CHINA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEPATITIS B; HUMAN; LONG TERM CARE; LUNG TUMOR; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; SEROCONVERSION; SIDE EFFECT; TREATMENT OUTCOME;

EID: 79956215777     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Lai CL, Ratziu V, Yuen MF, Poynard T. Viral hepatitis B. Lancet. 2003;362(9401):2089-2094.
2. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11(2):97-107.
3. Van Damme P, Zanetti AR, Shouval D, Van Herck K. Strategies for global prevention of hepatitis B virus infection. Adv Exp Med Biol. 2010;659:175-88.
4. Mendy ME, Welzel T, Lesi OA, Hainaut P, Hall AJ, Kuniholm MH, et al. Hepatitis B viral load and risk for liver cirrhosis and hepatocellular carcinoma in The Gambia, West Africa. J Viral Hepat. 2010;17(2):115-22.
5. Chan HL, Wong VW, Wong GL, Chim AM, Lai LH, Sung JJ. Evaluation of impact of serial hepatitis B virus DNA levels on development of hepatocellular carcinoma. J Clin Microbiol. 2009;47(6):1830-6.
6. Ghany M, Liang TJ. Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B. Gastroenterology. 2007;132(4):1574-85.
7. Jia JD, Zhuang H. A winning war against hepatitis B virus infection in China. Chin Med J (Engl). 2007;120(24):2157-8.
8. Chinese Society of Hepatology CMA, Chinese Society of Infectious Diseases CMA. Guideline on prevention and treatment of chronic hepatitis B in China (2005). Chin Med J (Engl).2007;120(24):2159-73.
9. European Association for The Study Of The L. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol. 2009;50(2):227-42.
10. Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2008;2(3):263-83.
11. Bartholomeusz A, Locarnini SA. Antiviral drug resistance: clinical consequences and molecular aspects. Semin Liver Dis. 2006;26(2):162-70.
12. Hsu LC, Lin SR, Hsu HM, Chao WH, Hsieh JT, Wang MC, et al. Ethnic differences in immune responses to hepatitis B vaccine. Am J Epidemiol. 1996;143(7):718-24.
13. So SK, Esquivel CO, Imperial JC, Garcia G, Monge H, Keeffe EB. Does Asian race affect hepatitis B virus recurrence or survival following liver transplantation for hepatitis B cirrhosis? J Gastroenterol Hepatol. 1999;14(Suppl):S48-S52.
14. Tan AT, Loggi E, Boni C, Chia A, Gehring AJ, Sastry KS, et al. Host ethnicity and virus genotype shape the hepatitis B virus-specific T-cell repertoire. J Virol. 2008;82(22):10986-97.
15. Adusumilli S. Tenofovir disoproxil fumarate for the treatment of hepatitis B. Drugs Today (Barc). 2009;45(9):679-85.
16. Buti M, Elefsiniotis I, Jardi R, Vargas V, Rodriguez-Frias F, Schapper M, et al. Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients. J Hepatol. 2007;47(3):366-72.
17. Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2006;354(10):1011-20.
18. Yao G, Chen C, Lu W, Ren H, Tan D, Wang Y, et al. Virologic, serologic, and biochemical outcomes through 2 years of treatment with entecavir and lamivudine in nucleoside-naive Chinese patients with chronic hepatitis B: a randomized, multicenter study. Hepatol Int. 2008;2(4):486-93.
19. Yao G, Zhou X, Xu D, Wang B, Ren H, Liu J, et al. Entecavir for the treatment of lamivudine-refractory chronic hepatitis B patients in China. Hepatol Int. 2007;1(3):373-81.
20. Leung N, Peng CY, Hann HW, Sollano J, Lao-Tan J, Hsu CW, et al. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir. Hepatology. 2009;49(1):72-9.
21. Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med. 2007;357(25):2576-88.
22. Hadziyannis SJ, Papatheodoridis GV, Dimou E, Laras A, Papaioannou C. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology. 2000;32(4 Pt 1):847-51.
23. Hou J, Yin YK, Xu D, Tan D, Niu J, Zhou X, et al. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial. Hepatology. 2008;47(2):447-54.
24. Kurashige N, Hiramatsu N, Ohkawa K, Yakushijin T, Kiso S, Kanto T, et al. Factors contributing to antiviral effect of adefovir dipivoxil therapy added to ongoing lamivudine treatment in patients with lamivudine-resistant chronic hepatitis B. J Gastroenterol. 2009;44(6):601-7.
25. Mihm U, Chan HL, Zeuzem S, Chim AM, Hui AY, Wong VW, et al. Virodynamic predictors of response to pegylated interferon and lamivudine combination treatment of hepatitis B e antigen-positive chronic hepatitis B. Antivir Ther. 2008;13(8):1029-37.
26. Choe WH, Hong SP, Kim BK, Ko SY, Jung YK, Kim JH, et al. Evolution of hepatitis B virus mutation during entecavir rescue therapy in patients with antiviral resistance to lamivudine and adefovir. Antivir Ther. 2009;14(7):985-93.
27. Hui CK, Zhang HY, Bowden S, Locarnini S, Luk JM, Leung KW, et al. 96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B. J Hepatol. 2008;48(5):714-20.